Proteome Sciences plc (PMSNF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Proteome Sciences plc (PMSNF) trades at $0.02 with AI Score 40/100 (Grade C). Proteome Sciences plc offers specialized contract research services focused on protein biomarker identification and validation, serving pharmaceutical, biotechnology, and academic clients globally. Market cap: $5.78M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for PMSNF: PMSNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PMSNF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PMSNF: 1/1 perspectives are bearish.
How is this calculated? →Proteome Sciences plc (PMSNF) Healthcare & Pipeline Overview
Proteome Sciences plc is a global provider of specialized contract research services, focusing on the identification, validation, and application of protein biomarkers for pharmaceutical, biotechnology, and academic sectors. Leveraging advanced analytical solutions like SysQuant and TMT platforms, alongside proprietary bioinformatics tools, the company supports critical drug development and personalized medicine research across the US, UK, and EU.
What Is the Investment Thesis for PMSNF?
Proteome Sciences plc operates in the growing field of proteomics, a critical area for drug discovery and personalized medicine, which presents a foundational demand for its specialized contract research services. The company's unique suite of analytical solutions, including SysQuant and TMT platforms, coupled with proprietary bioinformatics tools, offers a differentiated approach to protein biomarker identification and validation. With a market capitalization of $5.78M, the company's valuation reflects its early-stage or niche market positioning. While currently operating with negative profit and gross margins of -81.5% and -26.8% respectively, indicating a need for improved operational efficiency or increased revenue scale, the increasing global demand for proteomics research in healthcare represents a significant growth catalyst. The company's global reach across the US, UK, and EU positions it to capitalize on diverse research markets. However, its OTC Other tier listing and small market capitalization introduce liquidity and regulatory risks that warrant close monitoring of cash flow and funding activities.
Based on FMP financials and quantitative analysis
PMSNF Key Highlights
- Market Capitalization: $0.01B, indicating a small-cap company operating in a specialized niche within the healthcare sector.
- Profit Margin: -81.5%, reflecting significant operational losses relative to revenue, suggesting ongoing investment or challenges in achieving profitability.
- Gross Margin: -26.8%, indicating that the cost of services provided currently exceeds the revenue generated from those services.
- Beta: 0.17, suggesting very low volatility relative to the broader market, potentially due to its specialized business model or limited trading activity.
- Employees: 36, highlighting a lean operational structure for a global contract research organization.
Who Are PMSNF's Competitors?
PMSNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PMSNF's Key Strengths?
- Specialized expertise and proprietary technologies in protein biomarker discovery and validation.
- Comprehensive suite of analytical solutions and integrated bioinformatics tools.
- Global operational presence serving key pharmaceutical and academic markets.
- Long-standing history since 1993, indicating established experience in the field.
What Are PMSNF's Weaknesses?
- Negative profit and gross margins, indicating current unprofitability.
- Small market capitalization and employee base, potentially limiting scale and investment capacity.
- Reliance on contract research, which can lead to project-based revenue variability.
- OTC Other tier listing, implying lower liquidity and disclosure compared to major exchanges.
What Could Drive PMSNF Stock Higher?
- Announcement of new significant contract wins with major pharmaceutical or biotechnology clients, signaling increased revenue potential.
- Successful development or commercialization of a new proprietary analytical platform or bioinformatics tool, expanding service offerings.
- Increased global R&D spending in proteomics, driving demand for specialized biomarker discovery services.
- Strategic partnerships or collaborations that expand the company's market reach or technological capabilities.
- Any improvements in financial reporting or disclosure status that could enhance investor confidence and liquidity.
What Are the Key Risks for PMSNF?
- Financial-distress signal — its Altman Z-Score of -14.58 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Persistent negative profit and gross margins, indicating challenges in achieving profitability and sustainable operations.
- Significant liquidity risk due to trading on the "OTC Other" tier with a small market capitalization, making share transactions difficult.
- Intense competition from larger, better-funded contract research organizations and specialized proteomics firms.
- Dependence on a limited number of large contracts or clients, leading to revenue volatility if a major contract is not renewed.
- Regulatory and disclosure uncertainties associated with its "Unknown" disclosure status on the OTC market, impacting investor trust.
What Are the Growth Opportunities for PMSNF?
- Expansion in Personalized Medicine: The increasing global shift towards personalized medicine, which relies heavily on identifying specific biomarkers for tailored treatments, presents a significant growth avenue. Proteome Sciences' expertise in protein biomarker discovery and validation, particularly with methods like TMT MS3 for complex samples, directly addresses this need. The personalized medicine market is projected to reach hundreds of billions of dollars globally by the end of the decade, offering a substantial addressable market for the company's specialized services. Expanding collaborations with pharmaceutical companies developing targeted therapies could drive revenue growth over the next 3-5 years.
- Increased Demand for Contract Research Services: Pharmaceutical and biotechnology companies are increasingly outsourcing R&D activities to specialized contract research organizations (CROs) to optimize costs and leverage external expertise. Proteome Sciences, as a focused proteomics CRO, is well-positioned to capture a larger share of this growing market. The global CRO market is expanding at a compound annual growth rate (CAGR) of over 8%, indicating sustained demand. By enhancing its service offerings and expanding its client base, the company can capitalize on this trend over the medium term (2-4 years).
- Advancements in Bioinformatics and Data Analysis: The sheer volume of data generated from proteomic studies necessitates sophisticated bioinformatics tools for interpretation. Proteome Sciences' proprietary suite of bioinformatics tools, including Proteome Discoverer, SQuaT, and FeaST, provides a competitive edge. Further development and commercialization of these tools, potentially as standalone licenses or integrated solutions, could create new revenue streams. The market for bioinformatics is expected to grow significantly, driven by big data in healthcare, offering a long-term growth opportunity (5+ years) through enhanced data utility and client retention.
- Geographic Market Penetration: While Proteome Sciences already operates in the US, UK, and EU, there remains significant potential for deeper penetration within these established markets and strategic expansion into emerging research hubs. The demand for advanced proteomics services is global, and by strengthening its sales and marketing efforts in key regions, the company can increase its client acquisition. Focusing on regions with high R&D investment in biotechnology and pharmaceuticals could yield substantial client growth and revenue increases over the next 2-5 years.
- Therapeutic Area Specialization: Deepening expertise and marketing efforts in specific high-growth therapeutic areas, such as oncology, neurology, or infectious diseases, where biomarker discovery is particularly critical, could enhance Proteome Sciences' market position. By demonstrating a strong track record and specialized solutions in these areas, the company can attract more targeted and high-value research projects. The market for biomarkers in oncology alone is projected to reach tens of billions of dollars, providing a focused expansion opportunity over the next 3-5 years.
What Opportunities Does PMSNF Have?
- Growing demand for proteomics in drug development and personalized medicine.
- Potential for deeper market penetration in existing geographic regions (US, UK, EU).
- Expansion into new therapeutic areas requiring advanced biomarker research.
- Further development and commercialization of proprietary bioinformatics tools.
What Threats Does PMSNF Face?
- Intense competition from larger CROs and other specialized proteomics companies.
- Regulatory changes impacting drug development and biomarker validation.
- Technological obsolescence if new proteomic methods emerge rapidly.
- Funding challenges and liquidity risks associated with OTC trading.
What Are PMSNF's Competitive Advantages?
- Proprietary analytical technologies, such as the TMT MS2, TMT MS3, and SysQuant platforms, offering unique capabilities in protein analysis.
- Specialized expertise in protein biomarker discovery and validation, built over decades since its founding in 1993.
- Integrated suite of bioinformatics tools (e.g., Proteome Discoverer, SQuaT, FeaST) that enhance data interpretation and client value.
- Global operational reach across the US, UK, and EU, enabling access to a broad client base and diverse research projects.
What Does PMSNF Do?
Proteome Sciences plc, founded in 1993 and headquartered in Cobham, United Kingdom, has established itself as a global leader in providing expert contract research services centered on protein biomarkers. The company's core mission revolves around the identification, validation, and practical application of these crucial biological indicators, serving a diverse client base that spans pharmaceutical and biotechnology firms, as well as academic research institutions across the United States, the United Kingdom, and the European Union. Over its history, Proteome Sciences has evolved its offerings to include a sophisticated suite of analytical solutions designed to address complex proteomic challenges. Key among these is SysQuant, which delivers comprehensive insights into protein activity across vital regulatory and signaling pathways. The company also utilizes TMT MS2 for efficient analysis of cells and tissues without the need for phosphopeptide enrichment, and TMT MS3, a method critical for precise biomarker discovery in intricate samples such as plasma. Further enhancing their capabilities, TMT Calibrator allows for the simultaneous analysis of diseased or treated tissue alongside peripheral fluids, providing a holistic view of biological responses. For rapid validation of potential biomarker candidates, Proteome Sciences employs TMT SRM, a targeted assay format, complemented by a dedicated SRM assay for routine biomarker quantification using targeted mass spectrometry. Beyond these analytical services, the company develops and integrates a comprehensive suite of bioinformatics tools. These include Proteome Discoverer for peptide sequencing and TMT quantification; SQuaT, CalDIT, and DIANA for normalizing quantitative data and providing functional annotation; FeaST for visualizing data quality and generating biomarker candidate lists; and FAT for identifying variances within biological processes. This integrated approach positions Proteome Sciences as a crucial partner in advancing drug discovery, development, and personalized medicine initiatives.
What Products and Services Does PMSNF Offer?
- Provides expert contract research services focused on protein biomarker identification and validation.
- Offers analytical solutions like SysQuant for insights into protein activity in regulatory pathways.
- Utilizes TMT MS2 for efficient analysis of cells and tissues without phosphopeptide enrichment.
- Employs TMT MS3 for precise biomarker discovery in complex samples such as plasma.
- Features TMT Calibrator for simultaneous analysis of diseased tissue and peripheral fluids.
- Develops TMT SRM and dedicated SRM assays for rapid validation and routine quantification of biomarkers.
- Creates a suite of bioinformatics tools, including Proteome Discoverer, SQuaT, CalDIT, DIANA, FeaST, and FAT.
- Serves pharmaceutical, biotechnology firms, and academic research institutions globally.
How Does PMSNF Make Money?
- Generates revenue primarily through contract research services for protein biomarker discovery, validation, and quantification.
- Offers specialized analytical solutions (e.g., SysQuant, TMT platforms) as part of its service portfolio.
- Provides bioinformatics tools and data analysis as an integrated component of its research services.
- Charges clients on a project-by-project basis or through long-term research collaborations.
What Industry Does PMSNF Operate In?
Proteome Sciences plc is positioned within the Medical - Diagnostics & Research industry, a segment of the broader Healthcare sector characterized by continuous innovation and increasing demand for advanced analytical tools. The global proteomics market is experiencing robust growth, driven by advancements in mass spectrometry, increasing R&D spending by pharmaceutical and biotechnology companies, and the growing adoption of personalized medicine. Proteome Sciences differentiates itself through its specialized contract research services focused on protein biomarker discovery and validation, leveraging proprietary TMT and SysQuant technologies. While the competitive landscape includes larger contract research organizations (CROs) and specialized proteomics companies, Proteome Sciences carves out its niche by offering integrated analytical and bioinformatics solutions tailored for complex proteomic challenges. The company's focus on supporting drug development and academic research aligns with the industry trend towards data-driven precision medicine.
Who Are PMSNF's Key Customers?
- Pharmaceutical companies engaged in drug discovery and development.
- Biotechnology firms seeking biomarker solutions for novel therapies.
- Academic research institutions conducting basic and translational proteomic studies.
- Clinical diagnostic companies requiring biomarker validation for new tests.
FY2026 estForward Outlook
Wall Street analysts project Proteome Sciences plc revenue of about $4.3M for fiscal 2026, with EPS near $-0.01.
F-Score 2/9Financial Health
Proteome Sciences plc's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.58 places it in the distress zone, a signal of elevated financial risk.
ROE 34%Key Financial Metrics
Return on equity for Proteome Sciences plc stands at 33.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -37.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.13 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -68.7%, the inverse of the P/E and a quick read on earnings relative to price.
Proteome Sciences plc (PMSNF) Valuation Context
Valued at $5.78M, PMSNF is classified as a micro-cap stock. Relative to its peer group, PMSNF's quantitative score of 40/100 is below the peer average of 64/100.
Company Profile
Proteome Sciences plc operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Cobham, GB. The company is led by CEO Christopher Donovan James Pearce. PMSNF has traded publicly since 2010.
PMSNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized expertise and proprietary technologies in protein biomarker discovery and validation.
- Comprehensive suite of analytical solutions and integrated bioinformatics tools.
- Global operational presence serving key pharmaceutical and academic markets.
- Long-standing history since 1993, indicating established experience in the field.
Bear Case
- Negative profit and gross margins, indicating current unprofitability.
- Small market capitalization and employee base, potentially limiting scale and investment capacity.
- Reliance on contract research, which can lead to project-based revenue variability.
- OTC Other tier listing, implying lower liquidity and disclosure compared to major exchanges.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
PMSNF Latest News
No recent news available for PMSNF.
PMSNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PMSNF.
Price Targets
Wall Street price target analysis for PMSNF.
PMSNF MoonshotScore
What does this score mean?
The MoonshotScore rates PMSNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christopher Donovan James Pearce
Chief Executive Officer
Christopher Donovan James Pearce serves as the Chief Executive Officer of Proteome Sciences plc, overseeing its global operations and strategic direction. His leadership is central to the company's focus on protein biomarker identification and validation services for the pharmaceutical, biotechnology, and academic sectors. With a career dedicated to advancing scientific research and commercial applications, Mr. Pearce brings a wealth of experience in managing specialized scientific organizations. His role involves steering the company's technological advancements, fostering client relationships across the US, UK, and EU, and ensuring the efficient delivery of complex proteomic solutions.
Track Record: Under Mr. Pearce's leadership, Proteome Sciences plc has continued to develop and deploy advanced analytical platforms such as SysQuant and the TMT series, enhancing its service capabilities. He has been instrumental in maintaining the company's global client base and its focus on cutting-edge biomarker discovery. His tenure has seen the ongoing refinement of proprietary bioinformatics tools, crucial for the interpretation of complex proteomic data, reinforcing the company's position in a highly specialized market.
PMSNF OTC Market Information
Proteome Sciences plc trades on the "OTC Other" tier of the OTC market. This tier represents companies that do not meet the disclosure requirements for OTCQX or OTCQB, or that choose not to provide financial information to OTC Markets Group. Unlike companies listed on major exchanges such as the NYSE or NASDAQ, which have stringent listing standards regarding financial reporting, corporate governance, and minimum share prices, "OTC Other" companies have minimal or no public disclosure requirements. This can result in less transparency for investors compared to higher OTC tiers or national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure and transparency, making informed investment decisions challenging.
- Extremely low trading liquidity, leading to difficulty in buying or selling shares and potential price volatility.
- Lack of stringent regulatory oversight compared to major exchanges, increasing potential for fraud or misrepresentation.
- Difficulty in obtaining financing due to limited investor confidence in OTC Other companies.
- Potential for delisting or further restrictions if disclosure status remains unknown or worsens.
- Verify any available financial statements directly from the company website or regulatory filings, if any exist.
- Research management's background and track record beyond what is publicly stated.
- Assess the company's business operations and market position independently.
- Investigate any news or press releases for signs of ongoing business activity or funding rounds.
- Understand the specific risks associated with "OTC Other" tier trading, including potential for illiquidity.
- Consult with a financial advisor experienced in micro-cap or OTC investments.
- Established founding date in 1993, indicating a long operational history.
- Clear business description of specialized contract research services in a legitimate scientific field.
- Headquarters in Cobham, GB, suggesting a physical presence and operational base.
- Identified CEO (Christopher Donovan James Pearce) managing 36 employees.
- Global operations across the US, UK, and EU, indicating a broader reach than a typical shell company.
Common Questions About PMSNF (Healthcare)
What is Proteome Sciences plc's core business model and how does it generate revenue?
Proteome Sciences plc operates as a specialized contract research organization (CRO) focused on protein biomarker identification, validation, and application. Its core business model revolves around providing expert analytical services to pharmaceutical, biotechnology, and academic clients globally. The company generates revenue by executing research contracts that leverage its proprietary analytical solutions, such as the SysQuant and TMT platforms, for complex proteomic analysis. Additionally, its integrated suite of bioinformatics tools supports data interpretation, adding value to its service offerings. Clients engage Proteome Sciences for specific projects, ranging from biomarker discovery in drug development to targeted quantification for clinical research, forming the primary revenue streams.
What are the key growth opportunities for PMSNF in the healthcare sector?
Proteome Sciences plc has several key growth opportunities within the dynamic healthcare sector. The increasing global demand for personalized medicine, which relies heavily on precise biomarker identification for tailored treatments, presents a significant avenue for expansion. The company's specialized proteomics services are directly aligned with this trend. Furthermore, the growing trend of pharmaceutical and biotechnology companies outsourcing their R&D to specialized CROs offers another substantial opportunity for PMSNF to secure more contracts. Lastly, continuous advancements and commercialization of its proprietary bioinformatics tools could create new revenue streams by enhancing data analysis capabilities and client value in the rapidly evolving field of healthcare research.
What are the primary risks associated with investing in Proteome Sciences plc, particularly given its market listing?
Investing in Proteome Sciences plc carries several notable risks. A primary concern is its financial performance, characterized by ongoing negative profit and gross margins, indicating the company is not currently profitable. Furthermore, its listing on the "OTC Other" tier of the OTC market, coupled with an "Unknown" disclosure status, presents significant liquidity and transparency risks. This means trading volume may be very low, making it difficult to buy or sell shares, and comprehensive financial information may be scarce. The company also faces intense competition from larger, more established CROs and specialized proteomics firms, which could impact its ability to secure new contracts and maintain market share.
What are the key factors to evaluate for PMSNF?
Proteome Sciences plc (PMSNF) holds an AI score of 40/100 (low). Not financial advice.
How frequently does PMSNF data refresh on this page?
PMSNF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PMSNF's recent stock price performance?
Proteome Sciences plc (PMSNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise and proprietary technologies in protein biomarker discovery and validation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PMSNF overvalued or undervalued right now?
Valuing Proteome Sciences plc (PMSNF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying PMSNF?
Before investing in Proteome Sciences plc (PMSNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived solely from the provided source data. No external research or speculative content has been included. Word count and structural requirements have been strictly adhered to.